Could a simpler malaria vaccine dose protect more kids?

NCT ID NCT07036159

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether giving the RTS,S/AS01E malaria vaccine (Mosquirix) in lower doses or on different schedules is safe and triggers a strong immune response in healthy children aged 5 months to 5 years. The goal is to find simpler ways to vaccinate children in areas where malaria is common. Around 238 children will take part, and researchers will measure their antibody levels and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RTS,S/AS01E malaria vaccine (Mosquirix)
What this could lead to: If successful, this could show that simpler, lower-dose regimens of the malaria vaccine are safe and effective, making it easier and cheaper to protect more children.
What could go wrong: This is a small Phase 2a study (238 children) focused on safety and immune response, not on preventing malaria itself. Lower doses may not provide enough protection, and results may not apply to all settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

parasitic infectious disease Plasmodium falciparum malaria malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Kigali, Rwanda
GSK Investigational Site
RECRUITING

Kigali, Rwanda

More trials for these conditions

Other studies related to the condition(s) this trial covers.